fremanezumab
Ajovy · ATC code N02CD03
- Key facts
- Active substance
- fremanezumab
- Drug class
- Antimigraine
- ATC code
- N02CD03
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- AJOVY 225 mg solution for injection in pre-filled syringe / AJOVY 225 mg solution for injection in pre-filled pen
- Marketing authorisation holder
- Teva GmbH
- Information as of
- 2026-10-28
Key facts
Fremanezumab is a humanised monoclonal antibody that binds calcitonin gene-related peptide (CGRP). It is used for migraine prophylaxis in adults.
What it is used for
- Prophylaxis of migraine in adults who have at least 4 migraine days per month.
Dosing
- Ajovy (225 mg pre-filled syringe or pen): two dosing options – 225 mg once monthly or 675 mg every three months, given subcutaneously.
- When switching regimens, give the first dose of the new regimen on the next scheduled dosing date of the prior regimen.
- Treatment benefit should be assessed within 3 months after initiation; the need to continue should be evaluated regularly thereafter.
- Missed dose: resume as soon as possible; do not give a double dose.
- No dose adjustment for the elderly or in mild to moderate renal or hepatic impairment. Inject into abdomen, thigh or upper arm; self-injection possible after training.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
Important warnings
- Anaphylactic reactions have been reported rarely, mostly within 24 hours, some delayed; do not continue treatment after a serious hypersensitivity reaction.
- Patients with certain major cardiovascular diseases were excluded from clinical studies; no safety data are available in these patients.
- The name and batch number of the biological product should be recorded.
Side effects
- Very common: injection site reactions – pain (24%), induration (17%), erythema (16%); common injection site pruritus (2%).
- Uncommon: hypersensitivity reactions such as rash, pruritus, urticaria and swelling. Rare: anaphylactic reaction.
Interactions
- No pharmacokinetic interactions are expected; acute migraine treatments (analgesics, ergots, triptans) and other preventives did not affect fremanezumab pharmacokinetics.
Pregnancy and breastfeeding
- As a precaution, it is preferable to avoid use during pregnancy.
- Breast-feeding: a risk cannot be excluded in the first days after birth; afterwards consider only if clinically needed.
Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
This product has no separate US patient information.
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- AjovyTeva GmbH · EMEA/H/C/004833
Source: European Medicines Agency (EMA), product information
Turkey
- AjovyTEVA İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 3 more European countries
- Iceland
- Ajovy
- Liechtenstein
- Ajovy
- Norway
- Ajovy
EMA – Article 57 product data (EU/EEA), 2026-10-29
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Ajovy – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_en.pdf
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC N02CD.
Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.